Fibroblast Activation Protein Defines an Aggressive, Immunosuppressive EMT-associated Tumor Subtype in Highly Inflamed Localized Clear Cell Renal Cell Carcinoma

Teijo Pellinen, Lassi Luomala, Kalle Mattila, Annabrita Hemmes, Katja Välimäki, Oscar Brück, Lassi Paavolainen, Elisa Kankkunen, Harry Nísen, Petrus Järvinen, Leticia Castillon, Sakari Vanharanta, Paula Vainio, Olli Kallioniemi, Panu Jaakkola, Tuomas MirttibioRxiv 2024 · DOI

TL;DR

This study identifies a new, aggressive subtype of clear cell renal cell carcinoma (ccRCC) characterized by high immune infiltration, a specific EMT signature, and the expression of Fibroblast Activation Protein (FAP) on tumor cells. This FAP-positive subtype is linked to poorer survival and increased liver metastasis, suggesting FAP as a potential therapeutic target and biomarker.

What Problem Does This Paper Address?

Clear cell renal cell carcinoma (ccRCC) is known for its high immune infiltration, which often correlates with poor outcomes. While epithelial-to-mesenchymal transition (EMT), immune suppression, and cancer-associated fibroblasts (CAFs) are linked to worse prognoses in advanced ccRCC, their specific roles and interactions in localized disease were less clear. The authors aimed to dissect the complex tumor microenvironment (TME) in highly inflamed localized ccRCC to identify specific cell subsets and states that contribute to poor prognosis, particularly focusing on the interplay between EMT and immune cells.

Methods

The researchers employed multiplexed immunofluorescence (mIF), a powerful technique that allows for the simultaneous detection of multiple protein markers within a single tissue sample. They used a comprehensive panel of 33 antibodies to profile 1,728 tissue cores from 435 localized ccRCC patients. This allowed them to spatially characterize various cell types (immune cells, endothelial cells, fibroblasts, tumor cells) and their states within different regions of the tumor (center, invasive border, and adjacent benign tissue). They also utilized hierarchical clustering to identify distinct TME subsets and performed Kaplan-Meier survival analyses and Cox regression to assess the prognostic significance of identified markers. For validating FAP antibody specificity, they used CRISPR-Cas9 knockout in a cell line.

Datasets

The study utilized a dataset of 1,728 tissue cores collected from 435 localized ccRCC patients. This cohort was divided into an independent discovery set (n=196) and a validation set (n=239) to confirm findings. The tissue microarrays (TMAs) were constructed from formalin-fixed, paraffin-embedded (FFPE) surgical specimens.

Key Insights and Ideas

  • FAP as a dual marker: The study highlights that Fibroblast Activation Protein (FAP) isn't just a marker for cancer-associated fibroblasts (CAFs) but is also expressed on tumor cells themselves in an aggressive ccRCC subtype. This dual expression is a key finding.
  • EMT and immune suppression go hand-in-hand: The research strongly links the loss of epithelial markers (indicating EMT) with an increase in immunosuppressive immune cells (like exhausted T cells and M2 macrophages) and FAP-expressing CAFs. This suggests a coordinated effort by the tumor to evade immune surveillance.
  • Spatial context matters: The findings emphasize the importance of the tumor border, where EMT and FAP expression are particularly pronounced, suggesting this region is critical for disease progression and metastasis.
  • FAP as a prognosticator: Tumor cell FAP expression emerged as a more potent predictor of metastasis risk than patient age, underscoring its clinical relevance.

Key Results

  • CD45+ cell density predicts poor survival: Higher densities of CD45+ immune cells in tumor centers, borders, and even benign areas were associated with shorter recurrence-free survival (RFS).
  • FAP+ tumor cells define an aggressive subtype: In CD45high tumors, a low EpiStain phenotype (indicating EMT) was associated with a higher frequency of FAP+ ccRCC cells at the tumor border. These FAP+ tumors had a significantly lower 5-year RFS rate (26%) compared to FAP-negative CD45high tumors (50%).
  • FAP predicts liver metastasis: Stronger tumor cell FAP expression was significantly associated with a higher likelihood of liver metastasis, even after adjusting for clinical covariates.
  • FAP+ CAFs are enriched at tumor edges: FAP+ stromal cells were significantly increased at the tumor border in CD45high, EMT+ tumors and correlated with poor RFS.
  • Immunosuppressive microenvironment: Tumors with higher FAP levels and EMT phenotypes showed an enrichment of immunosuppressive immune cells, including exhausted T cells and M2-like macrophages.
  • FAP as an independent predictor: Tumor cell FAP expression was validated as an independent predictor of outcome in early-stage ccRCC (pT1-2) and in patients who later developed metastases and received sunitinib.

Limitations and Future Work

The authors acknowledge the retrospective design of their study. They were unable to analyze the impact of ccRCC cancer cell states and TME characteristics on the outcomes of adjuvant immunotherapy (like pembrolizumab) because the patients had undergone surgery before its widespread use. This is a key area for future research.

The study suggests several promising future directions:

  • FAP-targeted imaging (FAPI-PET): This could be explored for early detection of high-risk ccRCC to improve patient stratification and guide treatment decisions.
  • FAP-targeted therapies: Radioligand therapy and bispecific antibodies targeting FAP-expressing cells could offer novel treatment strategies, potentially by overcoming resistance to existing therapies and stimulating the immune system.
  • Integrating genomic profiling: Future studies should integrate observations of immune infiltration, stromal components, and cancer cell states with genomic profiling to better stratify patients for tailored treatments.
  • Investigating FAP in metastatic settings: The role of FAP in liver metastasis and its potential contribution to resistance against anti-angiogenic therapies warrants further investigation.

Summary updated

Abstract

ABSTRACT Clear cell renal cell carcinoma (ccRCC) is among the most immune-infiltrated cancers, where high inflammation correlates with poor clinical outcomes. While epithelial-to-mesenchymal transition (EMT), immunosuppression, and cancer-associated fibroblasts (CAFs) have been linked with poor prognosis in metastatic ccRCC, their relevance and interplay in localized disease remain uncertain. To address this gap, we performed single-cell spatial profiling of highly inflamed localized tumors to characterize interactions between EMT-associated cancer cells and immune subsets, aiming to identify tumor microenvironment cell subsets and states responsible for the poor prognosis in highly inflamed ccRCC. Multiplexed immunofluorescence imaging with a 33-marker panel was applied to 1,728 tissue cores collected from tumor centers, invasive borders, and adjacent benign tissue from 435 localized ccRCC patients. Independent discovery (n=196) and validation (n=239) cohorts were used to confirm the significance of identified prognostic markers. Hierarchical clustering revealed TME subsets enriched for CD45⁺ immune cells, CD31⁺ endothelial cells, or fibroblasts. High CD45⁺ cell density significantly correlated with poor recurrence-free survival across tumor regions, including tumor center, invasive border, and adjacent benign tissue. Within tumors exhibiting high CD45⁺ infiltration, EMT-associated cancer cells strongly expressed fibroblast activation protein (FAP) at invasive borders, independently predicting worse prognosis and increased risk of liver metastasis. Furthermore, CD45 high tumors with elevated FAP expression featured immunosuppressive FAP⁺ CAFs, M2-like macrophages, exhausted T cells, and regulatory T cells. Tumor-cell-specific FAP expression was validated as an independent prognostic biomarker in both early-stage localized ccRCC (pT1-2) and patients subsequently developing metastases who received sunitinib, highlighting its potential for improved patient stratification. Significance FAP expression identifies an aggressive, immunosuppressive EMT-associated subtype of localized ccRCC, uncovering critical interactions between cancer cells and the TME and revealing novel biological insights and therapeutic vulnerabilities driving early-stage ccRCC progression. Graphical Abstract Tumor-cell FAP Expression Defines an Aggressive, Immunosuppressive EMT Subtype in Highly Inflamed Localized ccRCC Localized ccRCC tumors were stratified by CD45⁺ immune infiltration, revealing that CD45 high tumors were associated with significantly poorer recurrence-free survival (5-year RFS rate: 39%). Among these, tumor cell-specific expression of fibroblast activation protein (FAP) identified a particularly aggressive subtype marked by epithelial-to-mesenchymal transition (EMT), reduced endothelial content, and an immunosuppressive tumor microenvironment enriched with M2-like macrophages, regulatory T cells, exhausted T cells, and FAP⁺ cancer-associated fibroblasts (CAFs). FAP⁺ tumors had an even lower 5-year RFS rate of 26%, compared to 50% in FAP⁻ CD45 high tumors. Tumor-cell FAP thus provides an additional layer of risk stratification within the CD45 high subgroup and reflects a biologically distinct, immune-evasive tumor state. These findings highlight FAP as both a potential therapeutic target and imaging biomarker in localized ccRCC.
BibTeX
@misc{pellinen2024fibroblast,
  author = {Teijo Pellinen and Lassi Luomala and Kalle Mattila and Annabrita Hemmes and Katja Välimäki and Oscar Brück and Lassi Paavolainen and Elisa Kankkunen and Harry Nísen and Petrus Järvinen and Leticia Castillon and Sakari Vanharanta and Paula Vainio and Olli Kallioniemi and Panu Jaakkola and Tuomas Mirtti},
  title = {{Fibroblast Activation Protein Defines an Aggressive, Immunosuppressive EMT-associated Tumor Subtype in Highly Inflamed Localized Clear Cell Renal Cell Carcinoma}},
  year = {2024},
  doi = {10.1101/2024.10.27.620479},
  howpublished = {bioRxiv},
}
Figure